Earlier this year the drug lecanemab made headlines after positive result in a clinical trial with people diagnosed with the early stages of Alzheimer’s disease. Lecanemab reduces Alzheimer’s progression Lecanemab is a monoclonal antibody consisting of the humanised version of a mouse antibody. It was developed to recognise, target and remove toxic beta-amyloid proteins that build up in […]